Latest Comments

Verily aims to become a prophet of human health

Verily aims to become a prophet of human health

Where you live matters: geographic differences in DAA treatment access

Where you live matters: geographic differences in DAA treatment access

Quality-of-life improvements: DAA treatment from the patient’s perspective

Quality-of-life improvements: DAA treatment from the patient’s perspective

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

FOURIER outcomes data highlights the importance of value in drug development

FOURIER outcomes data highlights the importance of value in drug development

Unmet needs in the liver cancer market mean it’s full of potential

Unmet needs in the liver cancer market mean it’s full of potential

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

Amgen and Cytokinetics: approaching acute heart failure from a different angle

Amgen and Cytokinetics: approaching acute heart failure from a different angle

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

When faster is not better: the 'surrogate' example

When faster is not better: the 'surrogate' example

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

PD-1s show early promise in melanoma brain metastases

PD-1s show early promise in melanoma brain metastases

How biomarker-driven cancer immunotherapy can benefit both patients and developers

How biomarker-driven cancer immunotherapy can benefit both patients and developers

Phase III failure puts the future of Alcobra in doubt

Phase III failure puts the future of Alcobra in doubt

Eli Lilly aims to dominate the migraine market

Eli Lilly aims to dominate the migraine market

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Intarcia Therapeutics' game-changing type 2 diabetes treatment is on the horizon

Intarcia Therapeutics' game-changing type 2 diabetes treatment is on the horizon

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market